ARKG Holdings of Repare Therapeutics (RPTX) - Updated Daily
TherapeuticsGene TherapyCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 1.35% | $447.40m |
| 🏋🏿♂️Weight Rank In ARKG | 🌏Country |
| 28 | 🇨🇦Canada |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 64 | |
| 🎫ARK Ownership Percent | |
| 6.24% | |
| Description | |
|---|---|
| repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com. | |
| Website | |
| reparerx.com |
Other ETFs That Hold RPTX
Research Notes and Commentary for RPTX
No Research Notes Found for RPTX